Vanda Pharmaceuticals, Inc. (VNDA) Misses Q1 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St headed for weekly gains as earnings season nears
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
HOVR, VFS, PGR, More
EPS Growth %: -78.9%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jet fuel prices near $5 per gallon in New York and Los Angeles
- SpaceX's spectrum deal puts SIRI's satellite assets in focus
- Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
